BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25976979)

  • 1. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
    Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
    Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables.
    Martin S; Wolters P; Baldwin A; Gillespie A; Dombi E; Walker K; Widemann B
    J Pediatr Psychol; 2012 Aug; 37(7):713-24. PubMed ID: 22353803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity.
    Loucas C; Wolters P; Toledo-Tamula MA; Rhodes A; Baldwin A; Goodwin A; Widemann B; Martin S
    Eur J Paediatr Neurol; 2022 May; 38():7-12. PubMed ID: 35334353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma.
    Lai JS; Jensen SE; Charrow J; Listernick R
    J Pediatr; 2019 Mar; 206():190-196. PubMed ID: 30413310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.
    Yang X; Yoo HK; Amin S; Cheng WY; Sundaresan S; Zhang L; Duh MS
    Childs Nerv Syst; 2022 Aug; 38(8):1513-1522. PubMed ID: 35579709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan.
    Lai JS; Jensen SE; Patel ZS; Listernick R; Charrow J
    Am J Med Genet A; 2017 Jan; 173(1):79-87. PubMed ID: 27666129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior.
    Krab LC; Oostenbrink R; de Goede-Bolder A; Aarsen FK; Elgersma Y; Moll HA
    J Pediatr; 2009 Mar; 154(3):420-5, 425.e1. PubMed ID: 18950800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
    Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey.
    Yoo HK; Porteous A; Ng A; Haria K; Griffiths A; Lloyd A; Yang X; Kazeem G; Barut V
    BMC Neurol; 2023 Nov; 23(1):419. PubMed ID: 37996843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.
    Wolkenstein P; Rodriguez D; Ferkal S; Gravier H; Buret V; Algans N; Simeoni MC; Bastuji-Garin S
    Br J Dermatol; 2009 Apr; 160(4):844-8. PubMed ID: 19067713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas.
    Hou Y; Allen T; Wolters PL; Toledo-Tamula MA; Martin S; Baldwin A; Reda S; Gillespie A; Goodwin A; Widemann BC
    Dev Med Child Neurol; 2020 Aug; 62(8):977-984. PubMed ID: 32052421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
    Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
    Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1.
    Allen TM; Struemph KL; Toledo-Tamula MA; Wolters PL; Baldwin A; Widemann B; Martin S
    Pain Pract; 2018 Nov; 18(8):969-978. PubMed ID: 29570943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.
    Martin S; Wolters PL; Toledo-Tamula MA; Schmitt SN; Baldwin A; Starosta A; Gillespie A; Widemann B
    Am J Med Genet A; 2016 Jun; 170(6):1462-70. PubMed ID: 27021207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
    Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
    Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1.
    Graf A; Landolt MA; Mori AC; Boltshauser E
    J Pediatr; 2006 Sep; 149(3):348-53. PubMed ID: 16939745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and Factors of Quality of Life Among Patients With Neurofibromatosis Type 1-Associated Craniofacial Plexiform Neurofibromas.
    Ren JY; Gu YH; Wei CJ; Huang X; Xu XW; Gu B; Zan T; Wang ZC; Li QF
    J Craniofac Surg; 2020; 31(2):347-350. PubMed ID: 31977693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.